Aiming to Bring Drug Combinations into Earlier Lines of Cancer Therapy, IDRx Raises $122M – MedCity News
A precision medicine is only as good as its target. Although targeted therapies now target many types of cancer, tumors still often develop mutations that help them escape the drug.…